160,500 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Acquired by Springhill Fund Asset Management HK Co Ltd

Springhill Fund Asset Management HK Co Ltd purchased a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 160,500 shares of the company's stock, valued at approximately $3,024,000. Nurix Therapeutics comprises about 4.9% of Springhill Fund Asset Management HK Co Ltd's investment portfolio, making the stock its 12th biggest holding. Springhill Fund Asset Management HK Co Ltd owned 0.21% of Nurix Therapeutics as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in shares of Nurix Therapeutics by 4,810.0% during the 4th quarter. Russell Investments Group Ltd. now owns 35,745 shares of the company's stock valued at $673,000 after acquiring an additional 35,017 shares during the last quarter. ExodusPoint Capital Management LP increased its position in Nurix Therapeutics by 147.5% during the fourth quarter. ExodusPoint Capital Management LP now owns 85,662 shares of the company's stock valued at $1,614,000 after acquiring an additional 51,049 shares during the last quarter. Cinctive Capital Management LP lifted its holdings in Nurix Therapeutics by 51.1% in the fourth quarter. Cinctive Capital Management LP now owns 158,972 shares of the company's stock valued at $2,995,000 after acquiring an additional 53,744 shares during the period. Bryce Point Capital LLC purchased a new position in Nurix Therapeutics in the fourth quarter worth about $538,000. Finally, Geode Capital Management LLC grew its stake in shares of Nurix Therapeutics by 9.5% during the 4th quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock valued at $29,870,000 after purchasing an additional 137,087 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on NRIX. Stifel Nicolaus lowered their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday. Needham & Company LLC dropped their price target on shares of Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday. Morgan Stanley upped their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research note on Monday, February 3rd. Royal Bank of Canada boosted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Three research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $30.44.

Insider Activity

In other news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the sale, the chief financial officer now directly owns 39,549 shares of the company's stock, valued at $785,047.65. This represents a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,326 shares of company stock valued at $213,449. 9.80% of the stock is currently owned by company insiders.

Nurix Therapeutics Stock Up 1.8 %

Nurix Therapeutics stock traded up $0.16 during midday trading on Friday, reaching $8.97. 274,518 shares of the stock traded hands, compared to its average volume of 870,056. The stock has a market cap of $683.46 million, a P/E ratio of -3.10 and a beta of 2.23. The stock's fifty day moving average is $14.22 and its 200-day moving average is $19.28. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same quarter last year, the firm earned ($0.76) EPS. On average, equities analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.